Latham & Watkins Advises Evoke Pharma on Acquisition by QOL Medical

Evoke Pharma, Inc. (NASDAQ: EVOK) (Evoke), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI^® (metoclopramide) nasal spray, and QOL Medical, LLC (QOL Medical), a privately held biopharmaceutical company specializing in treatments for GI and rare diseases, have announced that they have entered into a definitive agreement pursuant to which QOL Medical will acquire Evoke for US$11 per share in cash at closing. The transaction has been unanimously approved by the Boards of Directors of both companies and will be conducted via a tender offer.

Latham & Watkins LLP represents Evoke in the transaction with a corporate deal team led by Orange County partner Daniel Rees and San Diego partner Matthew Bush, with associates Shannon Cheng, Amy Lutfi, Ashley Campfield, and Joanna Yam, with assistance from Chloe Wallace, and a capital markets team of counsel Anthony Gostanian, with associate Shelby Harrison. Advice was also provided on executive compensation, employment and benefits matters by San Diego partner Holly Bauer, with associate Julie Voorhes; on regulatory/healthcare compliance matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings; on tax matters by Los Angeles partner Pardis Zomorodi and Houston partner Christine Mainguy, with associate Tessa Young; on intellectual property matters by San Diego partner Steven Chinowsky and counsels Darryl Steensma and Robert Yeh, with associate Kristina Funahashi; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Kathryn Parsons-Reponte; and on trademarks by New York counsel Lindsey Utrata.